Nanexa AB announced that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.746 SEK | +0.81% | +7.49% | -39.35% |
05-03 | Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.35% | 9.29M | |
-8.68% | 196M | |
-56.54% | 89.36M |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA